AstraZeneca ob Tuesday announced the appointment of Sheri McCoy and Deborah DiSanzo as Non-Executive Directors of the company. McCoy will also become a member of the Audit Committee.
McCoy’s appointment to the Board and the Audit Committee is effective October 1, 2017, while DiSanzo’s appointment to the Board is effective December 1, 2017.
Leif Johansson, the company’s Chairman is delighted to welcome Sheri McCoy and Deborah DiSanzo to the Board, as they are proven, seasoned executive leaders with experience and knowledge directly relevant to AstraZeneca’s business. “Sheri’s deep understanding of the pharmaceutical industry from her many years at Johnson & Johnson and Deborah’s distinguished career in healthcare and technology with IBM Watson Health and previously Philips Healthcare. We look forward to their contributions to the work of the Board of AstraZeneca,” Johannson said.